This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Prostate cancer	Enhancer of zeste homolog 2 (EZH2); protein kinase B (PKB; PKBA; AKT; AKT1)	<p>Cell culture studies suggest inhibiting the histone methyltransferase EZH2 could help treat prostate cancer. In androgen-independent prostate cancer cells, EZH2 methyltransferase activity and AKT-dependent phosphorylation of EZH2 were required for activation of target genes associated with castration-resistant disease. Next steps could include designing EZH2 inhibitors that block enzymatic activity and prevent AKT-mediated activation or testing the AKT plus EZH2 inhibitors in preclinical models of androgen-independent prostate cancer.</p> <p>SciBX 6(1); doi:10.1038/scibx.2013.11 Published online Jan. 10, 2013</p>	Patent and licensing status undisclosed	<p>Xu, K. <i>et al. Science</i>; published online Dec. 14, 2012; doi:10.1126/science.1227604 Contact: Myles Brown, Dana-Farber Cancer Institute, Boston, Mass. e-mail: myles_brown@dfci.harvard.edu Contact: X. Shirley Liu, same affiliation as above e-mail: xslu@jimmy.harvard.edu</p>